Experience and challenges from clinical trials with malaria vaccines in Africa

[1]  M. Tanner,et al.  Experience and challenges from clinical trials with malaria vaccines in Africa , 2013, Malaria Journal.

[2]  A. Olotu,et al.  A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E , 2012, PloS one.

[3]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[4]  B. Genton,et al.  A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.

[5]  B. Genton,et al.  A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.

[6]  Pedro Alonso,et al.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.

[7]  N. White.  A vaccine for malaria. , 2011, The New England journal of medicine.

[8]  C. Whitty.  The RTS,S malaria vaccine , 2011, BMJ : British Medical Journal.

[9]  K. Marsh,et al.  Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria , 2011, PloS one.

[10]  Kwaku Poku Asante,et al.  Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. , 2011, The Lancet. Infectious diseases.

[11]  C. Drakeley,et al.  Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine , 2011, Malaria Journal.

[12]  M. Tanner,et al.  Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children , 2011, PloS one.

[13]  R. Sauerwein,et al.  Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.

[14]  Ogobara K. Doumbo,et al.  A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.

[15]  Prashant Yadav,et al.  A Research Agenda for Malaria Eradication: Vaccines , 2019 .

[16]  Rajendra Maharaj,et al.  Operational strategies to achieve and maintain malaria elimination , 2010, The Lancet.

[17]  J. Farrar,et al.  Clinical Research in Resource-Limited Settings: Enhancing Research Capacity and Working Together to Make Trials Less Complicated , 2010, PLoS neglected tropical diseases.

[18]  O. Doumbo,et al.  Engaging diverse communities participating in clinical trials: case examples from across Africa , 2010, Malaria Journal.

[19]  Sumana Chakravarty,et al.  Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.

[20]  Adrian J F Luty,et al.  Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.

[21]  R. Chilengi.  Clinical development of malaria vaccines: Should earlier trials be done in malaria endemic countries? , 2009, Human vaccines.

[22]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[23]  W. Jaoko,et al.  European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership , 2009, BMC public health.

[24]  S. Abdulla,et al.  Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo, Tanzania , 2009, Health research policy and systems.

[25]  Q. Bassat,et al.  Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children , 2009, PloS one.

[26]  A. Roca-Feltrer,et al.  Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years , 2008, Tropical medicine & international health : TM & IH.

[27]  G. Pluschke,et al.  Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. , 2008, Clinical immunology.

[28]  R. Sinden,et al.  Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial , 2008, PloS one.

[29]  R. Chilengi,et al.  Humoral Responses to Plasmodium falciparum Blood-Stage Antigens and Association with Incidence of Clinical Malaria in Children Living in an Area of Seasonal Malaria Transmission in Burkina Faso, West Africa , 2007, Infection and Immunity.

[30]  C. Rogier,et al.  Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3 , 2007, PLoS medicine.

[31]  Peter A Singer,et al.  Grand Challenges in Global Health: Community Engagement in Research in Developing Countries , 2007, PLoS medicine.

[32]  J. Sattabongkot,et al.  Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer , 2007, Malaria Journal.

[33]  Peter G. Smith,et al.  Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. , 2007, Vaccine.

[34]  S. Andrieu,et al.  Attrition in geriatric research: how important is it and how should it be dealt with? , 2007, The journal of nutrition, health & aging.

[35]  D. Kwiatkowski,et al.  Valid Consent for Genomic Epidemiology in Developing Countries , 2007, PLoS medicine.

[36]  M. Kieny,et al.  A review of human vaccine research and development: malaria. , 2007, Vaccine.

[37]  S. Bull,et al.  Recruitment and retention of Latinos in a primary care-based physical activity and diet trial: The Resources for Health study. , 2006, Health education research.

[38]  Penelope Vounatsou,et al.  Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. , 2006, The American journal of tropical medicine and hygiene.

[39]  P. Alonso.  Malaria: deploying a candidate vaccine (RTS,S/AS02A) for an old scourge of humankind. , 2006, International microbiology : the official journal of the Spanish Society for Microbiology.

[40]  O. Doumbo,et al.  Community permission for medical research in developing countries. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  O. Doumbo.  Also see the archival list of the Essays on Science and Society. GLOBAL VOICES OF SCIENCE: It Takes a Village: Medical Research and Ethics in Mali , 2005, Science.

[42]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[43]  M Tanner,et al.  Relationships between the outcome of Plasmodium falciparum infection and the intensity of transmission in Africa. , 2004, The American journal of tropical medicine and hygiene.

[44]  D. Berwick,et al.  Quality improvement in the developing world. , 2002, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[45]  B. Lowe,et al.  Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2 , 2002, Parasite immunology.

[46]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[47]  A. Holder,et al.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. , 1999, Parassitologia.

[48]  B. Greenwood,et al.  IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. , 1998, The American journal of tropical medicine and hygiene.

[49]  C. Rogier,et al.  Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria , 1997, Infection and immunity.

[50]  W. Hawley,et al.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1 , 1996, Infection and immunity.

[51]  P. Deloron,et al.  IgG1 and IgG2 antibody responses to Plasmodium falciparum exoantigens correlate inversely and positively, respectively, to the number of malaria attacks. , 1996, FEMS immunology and medical microbiology.

[52]  R. Mshana,et al.  Immunologic responses to soluble exoantigens of Plasmodium falciparum in Gabonese children exposed to continuous intense infection. , 1994, The American journal of tropical medicine and hygiene.

[53]  T. Smith,et al.  Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.

[54]  A. Sabchareon,et al.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.

[55]  J. Stockman.  First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[56]  S. Rogerson.  Malaria in pregnancy and the newborn. , 2010, Advances in experimental medicine and biology.

[57]  Nawal M. Nour,et al.  Malaria and pregnancy: a global health perspective. , 2009, Reviews in obstetrics & gynecology.

[58]  R. Anders,et al.  Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. , 2009, Vaccine.

[59]  A. Hill.  Pre-erythrocytic malaria vaccines: towards greater efficacy , 2006, Nature Reviews Immunology.

[60]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[61]  P. Druilhe,et al.  Antibodies in falciparum malaria: what matters most, quantity or quality? , 1992, Memorias do Instituto Oswaldo Cruz.